Joint Stock Company Pharmstandard researches, develops, manufactures, and sells pharmaceutical products and medical equipment in the Russian Federation. The company operates through two segments, Production and Wholesale of Pharmaceutical Products; and Production and Wholesale of Medical Equipment. It offers drugs for the treatment of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer, and other diseases. The company primarily offers antiviral products, including Arbidol and Amixin; Pentalgin, a non-narcotic and anti-pyretic product; Complivit, a multivitamin with minerals; Terpincod and Codelac that are used as antitussives; Flucostat, a systemic agent for fungal infections; Afobazol, a tranquilliser; Corvalol, a hypnotic/sedative; and Phosphogliv, a hepatic protector and lipotropic product. It also provides prescription pharmaceuticals and third parties pharmaceuticals. In addition, Joint Stock Company Pharmstandard is involved in the sale of medical equipment; and central procurement, finance, and sundry activities; and venture investments operations. The company was formerly known as PJSC Pharmstandard and changed its name to Joint Stock Company Pharmstandard in May 2017. The company is headquartered in Moscow, Russia. As of January 18, 2021, operates as a subsidiary of MKOOO Augment Investments Limited.